Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Short term Debt (2016 - 2023)

Historic Short term Debt for Ligand Pharmaceuticals (LGNYZ) over the last 9 years, with Q1 2023 value amounting to $76.8 million.

  • Ligand Pharmaceuticals' Short term Debt changed N/A to $76.8 million in Q1 2023 from the same period last year, while for Mar 2023 it was $76.8 million, marking a year-over-year change of. This contributed to the annual value of $76.7 million for FY2022, which is N/A changed from last year.
  • According to the latest figures from Q1 2023, Ligand Pharmaceuticals' Short term Debt is $76.8 million.
  • Ligand Pharmaceuticals' Short term Debt's 5-year high stood at $115.0 million during Q2 2022, with a 5-year trough of $26.8 million in Q1 2019.
  • In the last 3 years, Ligand Pharmaceuticals' Short term Debt had a median value of $76.6 million in 2022 and averaged $66.5 million.
  • The largest annual percentage gain for Ligand Pharmaceuticals' Short term Debt in the last 5 years was 8824.16% (2019), contrasted with its biggest fall of 9325.0% (2019).
  • Over the past 3 years, Ligand Pharmaceuticals' Short term Debt (Quarter) stood at $27.1 million in 2019, then surged by 183.14% to $76.7 million in 2022, then rose by 0.12% to $76.8 million in 2023.
  • Its last three reported values are $76.8 million in Q1 2023, $76.7 million for Q4 2022, and $76.6 million during Q3 2022.